Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In a double-blind study, diclofenac sodium (Voltaren), 50 mg two or three times a day, was compared with placebo in 32 patients with pain localized to the temporomandibular joint (TMJ). The patients were allocated into two equally large groups. A visual analog scale was used to estimate the pretreatment degree of pain. The treatment effect was assessed as the frequency of joint and muscle pain and by the patients' own evaluation of improvement. The change in the clinical condition was assessed by tenderness to palpation of the TMJ and masticatory muscles and by mandibular mobility. The frequency of TMJ pain showed a greater reduction in the diclofenac group than in the placebo group, and there was a significant reduction of daily TMJ pain in the diclofenac group. The diclofenac group also showed a significant decrease in tenderness to palpation of the masticatory muscles in comparison with the placebo group. The patients with short duration of pain showed the best response to diclofenac. There was no evidence in this study to prove that diclofenac should be used as a primary treatment of TMJ pain, but it could be used as a complement to other treatments of acute TMJ pain.
 ...
PMID:Diclofenac sodium as an alternative treatment of temporomandibular joint pain. 881 Nov 36

Twenty-four surgical patients of both sexes without cardiac, hepatic, renal or endocrine dysfunctions were divided into two groups: 10 cardiac surgical patients submitted to myocardial revascularization and cardiopulmonary bypass (CPB), 3 females and 7 males aged 65 +/- 11 years, 74 +/- 16 kg body weight, 166 +/- 9 cm height and 1.80 +/- 0.21 m2 body surface area (BSA), and control, 14 surgical patients not submitted to CPB, 11 female and 3 males aged 41 +/- 14 years, 66 +/- 14 kg body weight, 159 +/- 9 cm height and 1.65 +/- 0.16 m2 BSA (mean +/- SD). Sodium diclofenac (1 mg/kg, im Voltaren 75 twice a day) was administered to patients in the Recovery Unit 48 h after surgery. Venous blood samples were collected during a period of 0-12 h and analgesia was measured by the visual analogue scale (VAS) during the same period. Plasma diclofenac levels were measured by high performance liquid chromatography. A two-compartment open model was applied to obtain the plasma decay curve and to estimate kinetic parameters. Plasma diclofenac protein binding decreased whereas free plasma diclofenac levels were increased five-fold in CPB patients. Data obtained for analgesia reported as the maximum effect (EMAX) were: 25% VAS (CPB) vs 10% VAS (control), P < 0.05, median measured by the visual analogue scale where 100% is equivalent to the highest level of pain. To correlate the effect versus plasma diclofenac levels, the EMAX sigmoid model was applied. A prolongation of the mean residence time for maximum effect (MRTEMAX) was observed without any change in lag-time in CPB in spite of the reduced analgesia reported for these patients, during the time-dose interval. In conclusion, the extent of plasma diclofenac protein binding was influenced by CPB with clinically relevant kinetic-dynamic consequences.
 ...
PMID:Diclofenac plasma protein binding: PK-PD modelling in cardiac patients submitted to cardiopulmonary bypass. 924 35

Thirty-one patients with acute renal colic were treated with Voltaren (Diclofenac Sodium, Ciba). The drug proved to be suitable for relieving, and stopping pain. Adverse effects were observed but in few cases. For this reason authors suggest a more extensive use of the drug.
 ...
PMID:The use of Voltaren (diclofenac sodium, Ciba) in acute renal colic. 926 25

A 29-year-old Hispanic man who had bilateral radial keratotomy (RK) and astigmatic keratotomy (AK) in his right eye 1 year previously went swimming in a lake. He subsequently developed foreign-body sensation and pain with a gradual decrease in vision over the following 5 weeks, despite treatment with ciprofloxacin hydrochloride (Ciloxan) and diclofenac sodium (Voltaren). The patient sought a second opinion. On examination, best corrected visual acuity was 20/40 in the right eye and 20/20 in the left. Slitlamp examination revealed mild conjunctival and scleral injection and a 3.5 mm diameter stromal infiltrate densest at the edges (Figure 1). The infiltrate involved one RK and one AK incision with gaping of both, approximately 90% depth incisions (Figure 2). The anterior chamber was deep and quiet. Examination was otherwise unremarkable. The cornea was scraped, but the smears were negative. The Ciloxan and Voltaren were stopped, and scopolamine four times a day was started. Cultures for aerobic, anaerobic, fungal, acid-fast bacilli, and Acanthamoeba were performed but showed no growth in the following week. Except for vascular ingrowth, there was no change in the appearance of the microbial keratitis during this week. An incisional biopsy and rescraping were performed, but there was again no growth of micro-organisms and no change in the microbial keratitis in the following 4 days. How would you manage this patient at this time?
 ...
PMID:Consultation section. Refractive surgical problem. 929 62

A comparative, multi-centre study, was conducted during June to December, 1996 to evaluate the efficacy and tolerance of Ketoprofen 100 mg Enteric Coated (EC) tablet and 100 mg intra-muscular injection; with that of Diclofenac Sodium 50 mg tablet and 75 mg intra-muscular injection in acute rheumatic and traumatic disorders. Total of 180 patients (90 per drug), were studied, 82 men and 98 women, between the ages of 18 and 75 years. The symptoms and the number of patients were backache 50, arthritis 64, frozen shoulder 32 and sprains 34. Pain was qualitatively assessed by visual analogue scale (VAS), XY pain index, pain at mobilization and the level of pain handicap. For pain (VAS 75-100) the treatment was initiated with an injectable bid, followed by tablets bid or tid. If the pain score on VAS was less than 75, tablets were given in a bid dosage. The duration of treatment was 15 days in each case. The overall complete relief of symptoms occurred in 25% (23/90) patients with Ketoprofen and in 10% (9/90) diclofenac sodium. Moderate to mild relief was found in 75% (67/90) cases with Ketoprofen and 87% (78/90) with diclofenac sodium. No pain relief was seen in 3% (3/90) with diclofenac sodium, as against no failure in pain relief in the ketoprofen group. Tolerance was found as excellent-good for ketoprofen in 72% (65/90) with diclofenac sodium in 50%, moderate to poor for ketoprofen in 28% (35/90) and with diclofenac sodium in 50% (45/90). Our results indicate that ketoprofen compared to diclofenac sodium is efficacious in acute rheumatic and traumatic injuries. Ketoprofen injection, compared to diclofenac sodium was found to be more effective in providing analgesia.
 ...
PMID:Study of efficacy and tolerance of ketoprofen and diclofenac sodium in the treatment of acute rheumatic and traumatic conditions. 1053 72

After oral- and maxillo-facial surgical interventions both Apranax and Cataflam proved to be satisfying against pain. Though there is no difference in the kinetics of the effect, we found Apranax more effective to relieve postoperative pain. Besides the fast elimination of pain the medicine significantly mitigate the symptoms of inflammation.
 ...
PMID:[Comparative study of the analgesic effect of Apranax and Cataflam after oral surgical procedures]. 1064 20

This paper reports the results of a pharmacokinetic study involving 24 healthy volunteers and designed to characterise the rate and extent of diclofenac absorption after the administration of a single dose of diclofenac (CAS 15307-86-5) potassium salt 50 mg in sachet (Voltfast) and tablet (Cataflam) formulations. Timed plasma concentrations of diclofenac during a 12-h-period after dosing were measured by means of HPLC with UV detection at 275 nm and a quantification limit of 10 ng/ml; the method was fully validated for pharmacokinetic purposes. These plasma concentrations were used to calculate Cmax, tmax, trapezoidal AUC0-t and AUC0-infinity and t1/2 by means of noncompartmental analysis. Cmax and tmax are the parameters expressing the rate of absorption, whereas the AUCs reflect the extent of absorption. The rate of absorption with the sachets proved to be very fast, reaching peak values at 10 min in seven subjects and at 15 min in the remaining subjects: mean time was 13.68 min, with concentrations at 5 min being 38% of Cmax. The average time to peak concentration with the tablets was 53.10 min. The extent of absorption of the sachets and tablets was similar, with AUC0-infinity values of respectively 1362 and 1214 ng.ml-1.h, and a 90% confidence interval 1.05-1.20. The highly soluble potassium salt of diclofenac was rapidly absorbed, especially in its sachet formulation, and thus appears to be an invaluable analgesic agent that is particularly useful for quick pain relief.
 ...
PMID:Pharmacokinetics of diclofenac after oral administration of its potassium salt in sachet and tablet formulations. 1068 15

An AIDS physician at New York's St. Vincent's Hospital reports considerable success with a topical formulation of the prescription drug Voltaren (a non-steroidal anti-inflammatory in the same class as Advil or Aleve). Dr. David Kaufman found the drug reduces pain and has essentially no side effects. The topical formulation, called Emulgel, is not sold in the United States. Information is requested about results using Emulgel and other brands of topical diclofenac sodium for treating neuropathy. Readers are also asked to share experiences with topical use of other anti-inflammatory drugs for relieving neuropathy. Contact information is provided.
 ...
PMID:Neuropathy: call for info. on Voltaren Emulgel (topical diclofenac sodium). 1136 14

Non-steroidal anti-inflammatory drugs (NSAID) are potent analgesic agents. They are indicated for rheumatoid arthritis, osteoarthritis, severe acute and prolonged chronic pain. A wide range of analgesic agents are available. The objective of this study was to assess the patient's knowledge of his illness, his knowledge familiarity with NSAID medications and their side effects and thereupon, to evaluate the awareness, utilization, satisfaction and expectations associated with current available treatment. During the year 2000, a randomized telephone screening questionnaire, was completed over a 2 month period for a sample group of the general Israeli population over 50 years of age. Of the 3179 persons contacted, 2028 responded and 292 persons were treated with NSAIDs and further investigated. Fifty percent suffered from chronic musculoskeletal pain, 22% had osteoarthritis, 10% had rheumatoid arthritis, and 18% had undefined chronic pain. The average age of the respondent was 65 years old. The average duration of treatment was 11 years. The most common drugs used by the 292 respondents that were taking NSAIDs were diclofenac (Voltaren)--51% and naproxen (Naxyn)--21%. Only 4% were treated with COX-2 specific inhibitors. Twenty percent of the respondents utilized more than one NSAID simultaneously. Forty seven percent of the patients had peptic ulcer disease but only 39% of them were simultaneously treated with an NSAID and a gastroprotective agent. Sixty eight percent of patients expected amelioration of symptoms while taking NSAIDs. Seventy seven percent of respondents were dissatisfied with treatment. The patients expressed that they did not have a reliable easily accessible source of information on their disorder or on available treatment options. Many respondents were not aware of their medical diagnosis. In general, patients were not aware of all the available NSAIDs or the side effects of gastrointestinal complications. Enhancement of information available to the patient is warranted to improve the provision of efficient therapy, reduce side effects and increase patient satisfaction from therapy.
 ...
PMID:[The lack of awareness of the Israeli population regarding gastrointestinal complications from non-steroidal anti-inflammatory drugs]. 1142 Aug 44

To reasons not yet completely understood, the pharmaceutical trademark Voltaren or Voltarol refers to the Italian scientist Alessandro Volta (1745-1827) who played an important role in the history of electricity. It is shown that electrotherapy has been used for the treatment of pain, gout and rheumatic disorders from ancient times to the present day. This therapeutic attempt was also discussed in scientific literature in the late 1960s, the time Voltaren was under development. Therefore, it is suggested that the electrotherapy of pain in history is a background for chosing this trademark.
 ...
PMID:The history of electrotherapy of pain--or: what Voltaren has to do with voltage. 1264 36


<< Previous 1 2 3 4 5 6 7 Next >>